CCL20 and melanoma: In line with the previous report on CCL20, we observed that high serum CCL20 concentrations before therapy are associated with significantly impaired PFS (p = 0.0033) and significantly lower overall survival rates (p = 0.042) in this single-center advanced melanoma cohort.